![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the Agreement, Shortwave will be the exclusive commercial partner in an investigator-initiated, open-label, phase II study of the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa (the "Trial").
Lead Product(s): Psilocybine
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Sheba Center for Eating Disorders
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 15, 2022